Fort Washington Investment Advisors Inc. OH Buys 14,301 Shares of Eli Lilly and Company $LLY

Fort Washington Investment Advisors Inc. OH increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 41.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,915 shares of the company’s stock after buying an additional 14,301 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Eli Lilly and Company were worth $37,322,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Braun Bostich & Associates Inc. increased its stake in shares of Eli Lilly and Company by 2.5% during the 2nd quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after purchasing an additional 13 shares during the last quarter. Rise Advisors LLC lifted its stake in Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after purchasing an additional 13 shares during the last quarter. Occidental Asset Management LLC grew its holdings in Eli Lilly and Company by 0.7% during the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after purchasing an additional 13 shares during the period. New Insight Wealth Advisors increased its position in Eli Lilly and Company by 3.4% in the second quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after buying an additional 13 shares during the last quarter. Finally, Dash Acquisitions Inc. raised its stake in shares of Eli Lilly and Company by 2.8% in the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock valued at $387,000 after buying an additional 13 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on LLY. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. HSBC reaffirmed a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Daiwa Capital Markets set a $1,230.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Finally, Daiwa America raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 16th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Stock Up 0.1%

Shares of NYSE LLY opened at $1,079.84 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a market cap of $1.02 trillion, a P/E ratio of 52.83, a P/E/G ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The business has a 50-day simple moving average of $997.74 and a two-hundred day simple moving average of $845.33.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the prior year, the business posted $1.18 earnings per share. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.